Chitosan and glyceryl monooleate nanostructures containing gemcitabine: Potential delivery system for pancreatic cancer treatment

AAPS PharmSciTech

Volumn 11, Issue 1, 2010, Pages 392-401

  Trickler, William J ^a   Khurana, Jatin ^a   Nagvekar, Ankita A ^a   Dash, Alekha K ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chitosan; Gemcitabine; Glyceryl monooleate; Nanostructure; Pancreatic cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHITOSAN; GEMCITABINE; GLYCEROL OLEATE; NANOMATERIAL; PLACEBO;

ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; EMULSION; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IC 50; IN VITRO STUDY; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; SOLVENT EXTRACTION; SURFACE CHARGE;

CELL SURVIVAL; CHITOSAN; DEOXYCYTIDINE; EMULSIONS; GLYCERIDES; HUMANS; INHIBITORY CONCENTRATION 50; NANOSTRUCTURES; PANCREAS; PANCREATIC NEOPLASMS;

EID: 77950915051     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9393-0     Document Type: Article

References (51)

1. A Jemal, et al. 2006 Cancer statistics, 2006 CA Cancer J Clin 56 2 106 130 10.3322/canjclin.56.2.106 16514137
2. R Freelove AD Walling 2006 Pancreatic cancer: diagnosis and management Am Fam Physician 73 3 485 492 16477897
3. LW Hertel, et al. 1990 Grindey Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine) Cancer Res 50 14 4417 4422 1:CAS:528:DyaK3cXkvFWjtb4%3D 2364394
4. W Plunkett, et al. 1995 Preclinical characteristics of gemcitabine Anticancer Drugs 6 Suppl 6 7 13 10.1097/00001813-199512006-00002 1:CAS:528:DyaK28XlsFyksg%3D%3D 8718419
5. HA Burris, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 2403 2413 1:CAS:528:DyaK2sXlsFKksLY%3D 9196156
6. V Heinemann, et al. 1988 Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′-difluorodeoxycytidine and 1-beta-d- arabinofuranosylcytosine Cancer Res 48 14 4024 4031 1:CAS:528:DyaL1cXlt1ajurc%3D 3383195
7. JL Abbruzzese, et al. 1991 A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 3 491 498 1:STN:280: DyaK3M7lsVymtg%3D%3D 1999720
8. JM Reid, et al. 2004 Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors J Clin Oncol 22 12 2445 2451 10.1200/JCO.2004.10.142 1:CAS:528:DC%2BD2cXpsVWlu7g%3D 15197207 (Pubitemid 41115403)
9. R Moog, et al. 2002 Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels Cancer Chemother Pharmacol 49 5 356 366 10.1007/s00280-002- 0428-4 1:CAS:528:DC%2BD38XjtFyls74%3D 11976829 (Pubitemid 34439336)
10. JR Mackey, et al. 1998 Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res 58 19 4349 4357 1:CAS:528:DyaK1cXmsVyqsbo%3D 9766663
11. M Pastor-Anglada, et al. 2004 Nucleoside transporters in chronic lymphocytic leukaemia Leukemia 18 3 385 393 10.1038/sj.leu.2403271 1:CAS:528:DC%2BD2cXhsV2qsbY%3D 14737075 (Pubitemid 38425849)
12. H Gourdeau, et al. 2001 Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines Cancer Res 61 19 7217 7224 1:CAS:528:DC%2BD3MXnsVeht7g%3D 11585758
13. J Yang, et al. 2006 Magnetic PECA nanoparticles as drug carriers for targeted delivery: synthesis and release characteristics J Microencapsul 23 2 203 212 10.1080/02652040500435444 1:CAS:528:DC%2BD28XmvVagt7w%3D 16754376 (Pubitemid 43840671)
14. J Yang, et al. 2006 Preparation of poly epsilon-caprolactone nanoparticles containing magnetite for magnetic drug carrier Int J Pharm 324 2 185 190 10.1016/j.ijpharm.2006.06.029 1:CAS:528:DC%2BD28XhtVOgu7%2FF 16872766 (Pubitemid 44528914)
15. CR Patra, et al. 2008 Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent Cancer Res 68 6 1970 1978 10.1158/0008-5472.CAN-07-6102 1:CAS:528:DC%2BD1cXjtFOhtrg%3D 18339879 (Pubitemid 351416584)
16. J Gang, et al. 2007 Magnetic poly epsilon-caprolactone nanostructure containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model J Drug Target 15 6 445 453 10.1080/10611860701453901 1:CAS:528:DC%2BD2sXnt1Witr0%3D 17613663 (Pubitemid 47073060)
17. B Stella, et al. 2007 Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules Int J Pharm 344 1-2 71 77 10.1016/j.ijpharm.2007.06.006 1:CAS:528:DC%2BD2sXhtV2qtb%2FK 17651931 (Pubitemid 47464827)
18. LH Reddy P Couvreur 2008 Novel approaches to deliver gemcitabine to cancers Curr Pharm Des 14 11 1124 1137 10.2174/138161208784246216 1:CAS:528:DC%2BD1cXmslKrsr0%3D 18473859 (Pubitemid 351982559)
19. LS Huang, et al. 2007 Preparation of gemcitabine polybutylcyanoacrylate nanoparticles Nan Fang Yi Ke Da Xue Xue Bao 27 11 1653 1656 1:CAS:528: DC%2BD1cXivFCksQ%3D%3D 18024282
20. CM Galmarini, et al. 2008 Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines Mol Cancer The 7 10 3373 3380 10.1158/1535-7163.MCT-08-0616 1:CAS:528:DC%2BD1cXht1ensbzO
21. JL Arias, et al. 2009 Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine J Drug Target 17 8 586 598 10.1080/10611860903105739 1:CAS:528:DC%2BD1MXhtVamurbM 19694612
22. Y Li, et al. 2009 Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells Cancer Res 69 16 6704 6712 10.1158/0008-5472.CAN-09-1298 1:CAS:528:DC%2BD1MXpvFejurc%3D 19654291
23. A Bernkop-Schnurch, et al. 2006 Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system Int J Pharm 317 1 76 81 10.1016/j.ijpharm.2006.02.044 16595166 (Pubitemid 43866341)
24. F Zheng, et al. 2007 Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study Life Sci 80 4 388 396 10.1016/j.lfs.2006.09.040 1:CAS:528: DC%2BD2sXht1Ghug%3D%3D 17074366 (Pubitemid 44958716)
25. AM De Campos, et al. 2001 Chitosan nanostructure: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A Int J Pharm 224 1-2 159 168 10.1016/S0378-5173(01)00760-8 11472825 (Pubitemid 32706495)
26. G Sandri, et al. 2007 Nanostructure based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models Eur J Pharm Biopharm 65 1 68 77 10.1016/j.ejpb.2006.07.016 1:CAS:528:DC%2BD28Xht1KlsL%2FK 16962751 (Pubitemid 44827693)
27. S Engstrom 1990 Drug delivery from cubic and other lipid-water phases Lipid Technol 2 42 45
28. ST Hyde, et al. 1984 A cubic structure consisting of a lipid bilayer forming in infinite periodic minimum surface of the gyriod type in the glycerylmonooleate-water system Z Krystallogar 168 213 219 1:CAS:528: DyaL2MXhsFymt7s%3D
29. WJ Trickler, et al. 2008 A novel nanoparticle formulation for sustained paclitaxel delivery AAPS PharmSciTech 9 2 486 493 10.1208/s12249-008-9063-7 1:STN:280:DC%2BD1cvltFantg%3D%3D 18431660
30. S Ganguly AK Dash 2004 A novel in situ gel for sustained drug delivery and targeting Int J Pharm 276 1-2 83 92 10.1016/j.ijpharm.2004.02.014 1:CAS:528:DC%2BD2cXjtlyqu70%3D 15113617 (Pubitemid 38542991)
31. WJ Trickler 2009 The in vitro sub-cellular localization and in vivo efficacy of novel Chitosan/GMO nanostructures containing paclitaxel Pharm Res 26 8 1963 1973 10.1007/s11095-009-9911-5 1:CAS:528:DC%2BD1MXmtVOrtrs%3D 19455409
32. S Jauhari AK Dash 2006 A mucoadhesive in situ gel delivery system for paclitaxel AAPS PharmSciTech 7 2 E53 10.1208/pt070253 16796370
33. B Sipos, et al. 2003 A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform Virchows Arch 442 5 444 452 12692724
34. S Yonezawa, et al. 1991 Differential mucin gene expression in human pancreatic and colon cancer cells Biochem J 276 Pt 3 599 605 1:CAS:528:DyaK3MXksVKqu7s%3D 2064602
35. H Takeuchi, et al. 2005 Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems Adv Drug Deliv Rev 57 11 1583 1594 10.1016/j.addr.2005.07.008 1:CAS:528:DC%2BD2MXhtFSis7fL 16169120 (Pubitemid 41443471)
36. H Takeuchi, et al. 2001 Mucoadhesive nanoparticulate systems for peptide drug delivery Adv Drug Deliv Rev 47 1 39 54 10.1016/S0169-409X(00)00120-4 1:CAS:528:DC%2BD3MXhvVajsrs%3D 11251244 (Pubitemid 32209231)
37. H Takeuchi, et al. 1994 Mucoadhesion of polymer-coated liposomes to rat intestine in vitro Chem Pharm Bull (Tokyo) 42 9 1954 1956 1:CAS:528: DyaK2MXktlOgsL8%3D
38. H Takeuchi, et al. 1996 Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes Pharm Res 13 6 896 901 10.1023/A:1016009313548 1:CAS:528:DyaK28Xjs1yrt7s%3D 8792429 (Pubitemid 26227747)
39. KA Howard, et al. 2006 RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system Mol Ther 14 4 476 484 10.1016/j.ymthe.2006.04.010 1:CAS:528:DC%2BD28XptFCgsb8%3D 16829204 (Pubitemid 44296092)
40. F Shikata, et al. 2002 In vitro cellular accumulation of gadolinium incorporated into chitosan nanostructure designed for neutron-capture therapy of cancer Eur J Pharm Biopharm 53 1 57 63 10.1016/S0939-6411(01)00198-9 1:CAS:528:DC%2BD38XltFCh 11777753 (Pubitemid 34036998)
41. H Takeuchi, et al. 2005 Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs Int J Pharm 303 1-2 160 170 10.1016/j.ijpharm.2005.06.028 1:CAS:528:DC%2BD2MXhtVamsr7N 16125348 (Pubitemid 41318033)
42. G Achanta, et al. 2001 Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage Cancer Res 61 24 8723 8729 1:CAS:528:DC%2BD38Xht1OnsA%3D%3D 11751391
43. LE Gerweck 1998 Tumor pH: implications for treatment and novel drug design Semin Radiat Oncol 8 3 176 182 10.1016/S1053-4296(98)80043-X 1:STN:280:DyaK1c3pvVemuw%3D%3D 9634494 (Pubitemid 28323476)
44. T Burke, et al. 1998 Interaction of 2′, 2′- difluorodeoxycytidine (gemcitabine) and formycin B with the Na+-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells J Pharmacol Exp Ther 286 3 1333 1340 1:CAS:528:DyaK1cXmt1Gqs7g%3D 9732397
45. JR Hammond, et al. 1999 [3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line J Pharmacol Exp Ther 288 3 1185 1191 1:CAS:528:DyaK1MXhs1Kisrs%3D 10027857
46. AM Bergman, et al. 2003 Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines Br J Cancer 88 12 1963 1970 10.1038/sj.bjc.6601011 1:CAS:528:DC%2BD3sXksVKjtbY%3D 12799644 (Pubitemid 36829675)
47. J Yao, et al. 2005 The mechanism of resistance to 2′, 2′-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line Zhonghua Zhong Liu Za Zhi 27 12 721 726 1:CAS:528:DC%2BD1cXhvFem 16483481
48. J Rejman, et al. 2004 Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis Biochem J 377 Pt 1 159 169 10.1042/BJ20031253 1:CAS:528:DC%2BD2cXis1Wnsg%3D%3D 14505488 (Pubitemid 38114443)
49. J Panyam, et al. 2002 Rapid endo-lysosomal escape of poly(dl-lactide-co- glycolide) nanostructure: implications for drug and gene delivery Faseb J 16 10 1217 1226 10.1096/fj.02-0088com 1:CAS:528:DC%2BD38XlslWrurY%3D 12153989 (Pubitemid 34815409)
50. MD Chavanpatil, et al. 2006 Nanostructure for cellular drug delivery: mechanisms and factors influencing delivery J Nanosci Nanotechnol 6 9-10 2651 2663 10.1166/jnn.2006.443 1:CAS:528:DC%2BD28XhtVKgu7nN 17048473 (Pubitemid 44579937)
51. N Nafee, et al. 2007 Chitosan-coated PLGA nanostructure for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides Nanomedicine 3 3 173 183 1:CAS:528: DC%2BD2sXhtVCms7%2FP 17692575